Abstract: The present invention relates to methods for synthesizing energetic compounds and intermediates thereof. Specifically, the present invention relates to methods for synthesizing adamantanes and intermediates that are useful in such synthesis. Synthesized intermediates are useful in the synthesis of bicyclic and tricyclic substituted adamantanes. Examples of various intermediates are: acyclic 2-nitromalonaldehyde intermediates, 2,6,9-tri-substituted-4,8-dinitro-2,6,9-triazabicyclo[3.3.1]nona-3,7-dienes and 2,6-dinitro-4,8,9,10-tetra-aza-4,8,9,10-tetra-substituted adamantanes. Intermediates synthesized according to the methods of the present invention are useful toward the synthesis of tetraaza-adamantanes, which can serve as precursors to potentially superior new high-energy-density compounds (HEDCs).

Abstract: The present invention relates to methods for synthesizing energetic compounds and intermediates thereof. Specifically, the present invention relates to methods for synthesizing adamantanes and intermediates that are useful in such synthesis. Synthesized intermediates are useful in the synthesis of bicyclic and tricyclic substituted adamantanes. Examples of various intermediates are: acyclic 2-nitromalonaldehyde intermediates, 2,6,9-tri-substituted-4,8-dinitro-2,6,9-triazabicyclo[3.3.1]nona-3,7-dienes and 2,6-dinitro-4,8,9,10-tetra-aza-4,8,9,10-tetra-substituted adamantanes. Intermediates synthesized according to the methods of the present invention are useful toward the synthesis of tetraaza-adamantanes, which can serve as precursors to potentially superior new high-energy-density compounds (HEDCs).

Abstract: The present invention relates to methods for synthesizing energetic compounds and intermediates thereof. Specifically, the present invention relates to methods for synthesizing adamantanes and intermediates that are useful in such synthesis. Synthesized intermediates are useful in the synthesis of bicyclic and tricyclic substituted adamantanes. Examples of various intermediates are: acyclic 2-nitromalonaldehyde intermediates, 2,6,9-tri-substituted-4,8-dinitro-2,6,9-triazabicyclo[3.3.1]nona-3,7-dienes and 2,6-dinitro-4,8,9,10-tetra-aza-4,8,9,10-tetra-substituted adamantanes. Intermediates synthesized according to the methods of the present invention are useful toward the synthesis of tetraaza-adamantanes, which can serve as precursors to potentially superior new high-energy-density compounds (HEDCs). The tricyclic intermediate compound has a structure of Formula III: where R is one of a benzyl, 4-methoxybenzyl, acetyl, nitro, formyl, allyl, and a carboethoxyl group.

Abstract: There are described compounds of the formula ##STR1## where n is 2 or 3, X and Y are each independently hydrogen, loweralkyl, or halogen, and R.sub.1 and R.sub.2 are each independently hydrogen, loweralkyl, cyano, beta,beta,beta-trichloroethyoxycarbonyl, cyclopropylmethyl, phenethyl, or cyanoethyl, but at least one of the two is loweralkyl, which are useful as antidepressant and analgesic agents; novel intermediate compounds for preparing said compounds; and methods for synthesizing the foregoing compounds.

Abstract: There are disclosed novel compounds having the formula ##STR1## where X is hydrogen, halogen (F, Cl, Br or I), loweralkyl or loweralkoxy; and R is --CH, --CONH.sub.2, --COOCH(CH.sub.3).sub.2, --COOH, --COO(CH.sub.2).sub.4 Cl, ##STR2## R.sub.1 and R.sub.2 being independently hydrogen or lower alkyl and R.sub.3 being ##STR3## an optical antipode thereof or a pharmaceutically acceptable acid addition salt thereof, which are useful as antihypertensive, analgesic and antiinflammatory agents, methods for synthesizing them, and pharmaceutical compositions comprising an effective amount of such a compound.

Abstract: There are disclosed novel compounds having the formula ##STR1## where each X is independently hydrogen, halogen (F, Cl, Br or I), loweralkyl or loweralkoxy; m is 1 or 2; R' is hydrogen or loweralkyl; and R is ##STR2## n being 1, 2 or 3, each of R.sub.1 and R.sub.2 being independently hydrogen or loweralkyl and R.sub.3 being ##STR3## an optical antipode thereof or a pharmaceutically acceptable acid addition salt thereof, which are useful as antihypertensive, analgesic and antiinflammatory agents, methods for synthesizing them, and pharmaceutical compositions comprising an effective amount of such a compound.

Abstract: This invention relates to substituted 8-phenylisoxazolo[4,3-e][1,4]diazepin-5-ones of the formula ##STR1## wherein R is lower alkyl; R.sub.1 is hydrogen, amino alkyl, propargyl and lower alkyl; X is oxygen and sulfur; and Y is halogen, trifluoromethyl, lower alkyl, lower alkoxy and hydrogen. The compounds of this invention display useful anxiolytic and anticonvulsant activities.

Abstract: This invention relates to substituted 8-phenylisoxazolo[4,3-e][1,4]diazepin-5-ones of the formula ##STR1## wherein R is lower alkyl; R.sub.1 is hydrogen, amino alkyl, propargyl and lower alkyl; X is oxygen and sulfur; and Y is halogen, trifluoromethyl, lower alkyl, lower alkoxy and hydrogen. The compounds of this invention display useful anxiolytic and anticonvulsant activites.